Evidence map›Paper›PMID 25848864›Full record

ArticleNature immunology2015

The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity.

Zaida G Ramirez-Ortiz, Amit Prasad, Jason W Griffith, William F Pendergraft, Glenn S Cowley, David E Root, Melissa Tai, Andrew D Luster, Joseph El Khoury, Nir Hacohen and 1 more

Open access · greenAbstract read
In one paragraph

Article in Nature immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. The biology of TREM receptors.Nature reviews. Immunology · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Zaida G Ramirez-OrtizCenter for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Amit PrasadCenter for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Jason W GriffithCenter for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
William F PendergraftUniversity of North Carolina Kidney Center, Burnett Womack Building, Chapel Hill, North Carolina, USA.
Glenn S CowleyBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
David E RootBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Melissa TaiCenter for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Andrew D LusterCenter for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Joseph El Khoury1] Center for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA. [2] Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Nir Hacohen1] Center for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA. [2] Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Terry K MeansCenter for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Massachusetts General Hospital · USBroad Institute · USHarvard University · USUniversity of North Carolina at Chapel Hill · US

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3M
High-throughput targeted mutagenesis of mouse stem cell linesU01HG004080 · NHGRI · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI DE JONG, PIETER J. · 2006 to 2010
$28.1M
Production of Targeted Null Mutations for 10,000 Genes in C57BL/6 ES CellsU01HG004085 · NHGRI · REGENERON PHARMACEUTICALS, INC. · PI VALENZUELA, DAVID MANUEL · 2006 to 2010
$25.3M
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
Research Training in Pulmonary Immunology and Allergy at MGHT32HL116275 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI David C Christiani, ANDREW D LUSTER · 2013 to 2026
$8.6M
UCD KOMP PROJECT REPOSITORYU42RR024244 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LLOYD, KC KENT · 2007 to 2010
$7.9M
Generation of a comprehensive panel of reagents for research on scavenger receptoU24AI082660 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI EL-KHOURY, JOSEPH EL, STUART, LYNDA · 2009 to 2013
$4.7M
Mechanisms of anti-fungal immunity mediated by SCARF1 and CD36R01AI084884 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MEANS, TERRY K · 2010 to 2014
$2.1M
Role of SCARF1 in Human LupusK01AR066716 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAMIREZ-ORTIZ, ZAIDA GISELA · 2014 to 2019
$663k
Lupus Serum Signaling Through Toll-Like Receptor 9K01AR051367 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI MEANS, TERRY K · 2005 to 2009
$539k
In vivo validation and characterization of allelic variants in lupusF32DK097891 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI PENDERGRAFT, WILLIAM FRANKLIN · 2012 to 2013
$82k
NCRR NIH HHS U42 RR024244NCRR NIH HHS U42RR024244NHGRI NIH HHS U01 HG004080NHGRI NIH HHS U01HG004080NHGRI NIH HHS U01 HG004085NHGRI NIH HHS U01HG004085NHLBI NIH HHS T32 HL116275NIAID NIH HHS R01 AI084884NIAID NIH HHS R01-AI084884NIAID NIH HHS T32 AI007061NIAID NIH HHS T32-AI007061NIAID NIH HHS U24 AI082660NIAMS NIH HHS K01 AR051367NIAMS NIH HHS K01-AR051367NIAMS NIH HHS K01 AR066716NIAMS NIH HHS K01-AR066716NIDDK NIH HHS F32 DK097891NIDDK NIH HHS F32-DK097891NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

The molecules and pathways that fine-tune innate inflammatory responses mediated by Toll-like receptor 7 (TLR7) remain to be fully elucidated. Using an unbiased genome-scale screen with short hairpin RNA (shRNA), we identified the receptor TREML4 as an essential positive regulator of TLR7 signaling. Macrophages from Treml4(-/-) mice were hyporesponsive to TLR7 agonists and failed to produce type I interferons due to impaired phosphorylation of the transcription factor STAT1 by the mitogen-activated protein kinase p38 and decreased recruitment of the adaptor MyD88 to TLR7. TREML4 deficiency reduced the production of inflammatory cytokines and autoantibodies in MRL/lpr mice, which are prone to systemic lupus erythematosus (SLE), and inhibited the antiviral immune response to influenza virus. Our data identify TREML4 as a positive regulator of TLR7 signaling and provide insight into the molecular mechanisms that control antiviral immunity and the development of autoimmunity.

Indexed as

AnimalsAutoantibodiesAutoimmunityCells, CulturedCytokinesHumansImmunity, InnateInflammation MediatorsInterferon Type ILupus Erythematosus, SystemicMacrophagesMembrane GlycoproteinsMiceMice, Inbred C57BLMice, Inbred MRL lprMice, KnockoutAutoantibodiesCytokinesInflammation MediatorsInterferon Type IMembrane GlycoproteinsMyeloid Differentiation Factor 88p38 Mitogen-Activated Protein KinasesReceptors, ImmunologicRNA, Small InterferingSTAT1 Transcription FactorTlr7 protein, mouseToll-Like Receptor 7Treml4 protein, mouse

Identifiers

PMID25848864
PMCPMC4406861
OpenAlexW2003614717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.